How does Aceminid work?

Asciminib (scemblix/asciminib) is a prescription drug used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+) in the chronic phase (CP) in adults with: CML), who have previously received 2 or more T315I mutations CPTyrosine kinase inhibitors (TKIs)Ph+CMLTreatment.

Aceminibis a targeted therapy that works by specifically targeting the ABLmyristoyl pocket (STAMP ), a site of action that is different from other kinase inhibitors. This different way of working is important for people with Ph+ CML who have not responded adequately to other treatments or have troublesome side effects. It may also be used in patients with chronic myelogenous leukemia with the T315I mutation - Ph+ - a mutation that prevents certain tyrosine kinase inhibitors from working.

Aceminibis anABL/BCR-ABL1tyrosine kinase inhibitor. Aximiniinhibits the ABL1kinase activity of the BCR-ABL1 fusion protein by binding to the ABLmyristoyl pocket. In studies conducted in vitro or in animal models of chronic myelogenous leukemia, aceminib showed activity against wild-type BCR-ABL1 and several mutant forms of the kinase, including the T315I mutation. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0